Fierce Healthcare
NOVEMBER 19, 2024
More than half of health system and health plan executives say AI is an immediate priority, and 73% are increasing their investments in the technology, a new C-suite survey finds. | More than half of health system and health plan executives say AI is an immediate priority, and 73% are increasing their investments in the technology, a new C-suite survey finds.
The Checkup by Singlecare
NOVEMBER 19, 2024
Adderall is a controlled prescription medication commonly used to treat attention deficit hyperactivity disorder ( ADHD ). It is also approved by the Food and Drug Administration (FDA) to promote wakefulness in people with narcolepsy , a sleep disorder. The standard, immediate-release Adderall is usually taken two or three times per day, while extended-release Adderall XR is taken once daily.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Marketing Network
NOVEMBER 20, 2024
Table of Contents Sr# Headings 1 Introduction 2 What Is Display Advertising? 3 Why Display Advertising Matters in Pharma 4 Key Benefits of Display Advertising 5 Targeting: Reaching the Right Audience 6 Personalization in Display Ads 7 Case Study: Successful Pharma Display Campaigns 8 Choosing the Right Platforms 9 Metrics to Track for ROI Success 10 Regulatory Challenges and Solutions 11 The Role of Branded Drugs in Display Ads 12 Creative Best Practices for Display Ads 13 Aligning Display Ads w
STAT
NOVEMBER 20, 2024
Schrödinger CEO Ramy Farid wants you to know that his company isn’t an AI company…but he’ll call it that if you want to. The company, founded in 1990, started out by making software that used the basic laws of physics to laboriously and exactly predict how molecules will interact with each other in space. Those calculations, rooted in the field of computational physics, needed lots of expensive and time-consuming computing power to run, and many people abandoned those t
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmafile
NOVEMBER 18, 2024
This month, the Chalmers University of Technology in Sweden have published the results of a study demonstrating that resistant bacteria, when paired with material equipped with antibacterial peptides, can regain susceptibility to antibiotics. The study, conducted in a laboratory environment, concluded that antibiotics – such as oxacillin – could achieve an increase in their bactericidal […] The post Antibacterial peptides instrumental in efficiency against resistant bacteria appeared first
The Checkup by Singlecare
NOVEMBER 22, 2024
Ozempic (semaglutide) has made its way into headlines and water-cooler conversations largely due to its off-label use for weight loss more than its approved use for Type 2 diabetes mellitus. The glucagon-like peptide-1 (GLP-1) receptor agonist helps the pancreas release insulin and lowers blood sugar. It also mimics the GLP-1 hormone that tells your brain you’re full.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
NOVEMBER 22, 2024
The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart disease — the first new treatment for the condition in over five years and the company’s first significant commercial product. The drug, known scientifically as acoramidis, will be sold by BridgeBio under the brand name Attruby.
Fierce Pharma
NOVEMBER 18, 2024
With several high-profile manufacturing outlays already in the books in Europe this year, Sanofi is returning to the bloc in a bid to boost production for a long-approved transplant treatment and a | Sanofi has unveiled a 40 million euro investment at its Lyon Gerland biomanufacturing site in France. The cash infusion will help bolster local production of the company’s polyclonal antibody Thymoglubulin for kidney transplant rejection, as well as expected future capacity needs for the type 1 diab
The Checkup by Singlecare
NOVEMBER 22, 2024
Wegovy (semaglutide) is a once-a-week injection that’s approved by the Food and Drug Administration (FDA) to: Reduce excess body weight and maintain weight reduction in: Adults with a body mass index (BMI) of 30 or higher Adults with a BMI of 27 or higher who also have weight-related medical problems, such as high cholesterol or high blood pressure Adolescents ages 12–17 who are at or above the 95th percentile on sex- and age-specific growth charts Reduce the risk of major adverse cardiovascu
European Pharmaceutical Review
NOVEMBER 18, 2024
Sanofi is investing over €40 million in its Lyon Gerland site, supporting antibody bioproduction in France. A portion of this, €25 million, will be directed toward production and development of Sanofi’s second generation of its polyclonal antibody Thymoglubulin. It is used for transplantation and is manufactured exclusively at the Lyon Gerland site, Sanofi stated.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
NOVEMBER 19, 2024
When Makena, a drug designed to prevent preterm births, hit the market in 2011 at $1,500 per dose, it drew rife backlash. The drug was based on an active ingredient that had been available for many years at a much lower cost. Confronted with the public outcry, the FDA took an unusual step: It allowed pharmacies to continue making their own copies of the drug through the practice of pharmacy compounding, selling it at a fraction of Makena’s price.
Pharmafile
NOVEMBER 19, 2024
18 November 2024 – Manchester, UK – Chiesi Group, an international biopharmaceutical company focused on research, has been named one of the 25 World’s Best Workplaces™ in 2024 by Great Place To Work® (GPTW) and Fortune magazine, ranking 23rd on this year’s list.The news marks the first time any European pharmaceutical company has achieved the […] The post Great Place To Work® and Fortune Name Chiesi Group No. 23in 2024 World’s Best Workplaces™ List appeared first on Pharmafile.
The FDA Law Blog
NOVEMBER 19, 2024
By John W.M. Claud & Mark I. Schwartz — Over the past few days, we’ve been blogging about changes that are sure to come to FDA under Trump 2.0. Calls to more generally gut Federal agencies are everywhere, including from Robert F. Kennedy, Jr., the current nominee to lead the department of Health and Human Services. But shedding regulators in sensitive areas like drug manufacturing—even in the era of influencer-driven medicine—can lead to compromises in safety and efficacy, especially when FD
European Pharmaceutical Review
NOVEMBER 21, 2024
Can cartridges be used as a standard method for assessing endotoxins across various sample types throughout the industry? A : FDA-licensed cartridges utilise the kinetic chromogenic method and are fit to test any type of endotoxin sample including, but not limited to, waters, raw materials, in-process samples, final products, medical devices and radiopharmaceuticals.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT
NOVEMBER 19, 2024
Although more pharmaceutical companies are tailoring their business models to focus on low-income countries, a new analysis finds that overall industry efforts remain limited and patient access continues to suffer as a result. Notably, momentum has stalled in reaching licensing deals that are designed to make lower-cost generic drugs available in parts of the world where brand-name medicines are unaffordable, and few companies have pursued technology transfer agreements.
pharmaphorum
NOVEMBER 18, 2024
Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 receptor agonist class.The results from the SUMMIT trial of tirzepatide in obese patients with heart failure with preserved ejection fraction (HFpEF) showed that Lilly's drug cut the risk of cardiovascular mortality and worsening heart failure events by 38% over a median follow-up of roughly two years.
Board Vitals - Pharmacist
NOVEMBER 21, 2024
Before applying to NP school, one of the most important questions that you should answer for yourself is “What type of nurse practitioner do I want to become?” While many of us have experience working in a certain setting (ICU, clinic, emergency room, general pediatric floor, etc.) or with a certain population (babies, children, women, older adults, etc.), that does not mean that we automatically have a specialty in mind when considering becoming a nurse practitioner.
European Pharmaceutical Review
NOVEMBER 19, 2024
Novartis Pharma AG has agreed to a radiotherapeutic radioligand therapy-focused license and collaboration with Ratio Therapeutics. Through this deal, Ratio is eligible to receive milestone payments up to $745 million. The collaboration will utilise Ratio’s expertise in radioligand therapy and its technology platforms for development of a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
STAT
NOVEMBER 16, 2024
California has detected the country’s first case of a new mpox strain that is spreading from person to person. The infected individual had recently traveled from Eastern Africa, where multiple countries are battling transmission of this virus. The individual was treated in a health facility in San Mateo County and is in isolation at home, the California Department of Public Health announced in a statement released Saturday.
The FDA Law Blog
NOVEMBER 18, 2024
By Jennifer D. Newberger & Jeffrey N. Gibbs — On Thursday, November 14, President-Elect Trump announced his pick of Robert Kennedy, Jr., for Secretary of Health and Human Services (HHS). Although not altogether surprising, the formality of an official announcement still came as a shock to many of us who work in areas regulated by HHS, as well as to many others in the public health arena.
Fierce Pharma
NOVEMBER 19, 2024
After a labeling mix-up prompted a recall of a popular panic disorder drug this summer, Endo’s U.S. subsidiary is widening the scope of its product pull. | Endo USA is expanding its previous recall of orally disintegrating clonazepam tablets to include more than a dozen additional product lots. The recall is being issued thanks to an “error by a third-party packager” that led to certain cartons displaying the wrong strength and National Drug Code for the product they contain, Endo said.
European Pharmaceutical Review
NOVEMBER 21, 2024
Articles in Issue 5 of European Pharmaceutical Review include: FOREWORD ICH Q6(R1): test criteria and specifications Dave Elder David P Elder Consultancy CELL & GENE THERAPY How automation and digital technologies will unlock the full potential of advanced therapies Dr Stephen Ward CGT Catapult Hydrogel encapsulation: unlocking the potential of cell therapies for targeted treatments Dr Stephen Harrington and Francis Karanu Likarda SUSTAINABILITY Transitioning to digital product information t
STAT
NOVEMBER 19, 2024
Merck said a new formulation of the best-selling drug, Keytruda, appears to deliver similar blood levels of the medicine when it is given as a shot as when it is given intravenously. For Merck, the new under-the-skin, or subcutaneous, formulation of Keytruda could represent a major way of holding on to a larger share of Keytruda’s $25 billion in annual sales than would otherwise occur when the medicine’s U.S. patent expires in 2028.
Board Vitals - Pharmacist
NOVEMBER 21, 2024
Paying for NP school can be a significant source of stress for many students. The conventional method of paying out-of-pocket is feasible for some, but not all, students. However, there are multiple other options to consider for payment assistance. Scholarships Most universities have a financial aid office responsible for guiding students on scholarship opportunities.
Fierce Pharma
NOVEMBER 22, 2024
While Johnson & Johnson hopes to soon resolve more than 60,000 talc lawsuits with an $8 billion bankruptcy settlement in the United States, its baby power problems are only just beginning in th | While Johnson & Johnson hopes to soon resolve more than 60,000 talc lawsuits with an $8 billion bankruptcy settlement in the United States, its baby power problems are only just beginning in the U.K.
European Pharmaceutical Review
NOVEMBER 21, 2024
In June, the US Food and Drug Administration’s (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) rejected 1 Lykos Therapeutics’ psychedelic new drug application (NDA) for midomafetamine (MDMA) capsules used alongside MDMA-assisted therapy to treat post-traumatic stress disorder (PTSD) in adults. With the recent failure of Lykos’ trial, how do you see the future of psychedelic therapies in research, especially in treating disorders like depression, PTSD, and substance use diso
STAT
NOVEMBER 22, 2024
The battle over prescription drug discounts offered to hospitals under a federal program escalated as Sanofi became the third pharmaceutical company to disclose plans to change the way it will make payments. In a letter sent to hospitals and clinics on Friday, Sanofi indicated that certain hospitals covered by the 340B Drug Discount Program would receive credits for medicines ordered at full price from a wholesaler.
Fierce Healthcare
NOVEMBER 22, 2024
Instacart, the online grocery delivery platform, has launched a new Supplemental Nutrition Assistance Program (SNAP) eligibility screener on its website for consumers and clinicians. | The screener, available on Instacart’s EBT SNAP information page, lets anyone nationwide quickly and anonymously check whether they may be eligible for SNAP benefits.
Fierce Pharma
NOVEMBER 19, 2024
Two months after Roche scored FDA approval for its subcutaneous ve | Two months after Roche scored FDA approval for its subcutaneous version of PD-LI inhibitor Tecentriq, Merck has achieved a key milestone in lining up its checkpoint inhibitor Keytruda to follow suit. On Tuesday, the company revealed that its subcutaneous formulation of Keytruda has aced a phase 3 trial, demonstrating non-inferiority to the immunotherapy’s intravenous version.
European Pharmaceutical Review
NOVEMBER 21, 2024
Several new appointments were announced by Amgen and Pfizer yesterday, focusing on R&D functions. Pfizer Inc. is appointing Dr Chris Boshoff , PhD, as Chief Scientific Officer and President, Research & Development. Dr Boshoff will begin this new role on 1 January 2025 and will oversee all R&D functions across every therapeutic area in the company.
STAT
NOVEMBER 21, 2024
LONDON — The stacks of brightly colored disposable e-cigarettes, touting flavors like cotton candy ice and greengrape melon and often looming over the not-dissimilar-looking candy displays, have become a commonplace sight in convenience stores in both the U.S. and the U.K. But here, they’re on their way out.
The FDA Law Blog
NOVEMBER 17, 2024
By JP Ellison — The word unprecedented has been used a lot in the past two weeks. Perhaps appropriately. Below is some precedent that’s been on this blogger’s mind recently and that may be relevant in the coming days, weeks, and months: Tummino v. Hamburg. Why? The HHS Secretary intervened in an FDA approval decision. The court ruled the agency’s action was arbitrary and capricious and entered a mandatory injunction ordering FDA to make the drug available.
Pharmaceutical Commerce
NOVEMBER 22, 2024
In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Gaurav Gupta, managing director and head of R&D at Kotter, comments on the specific technical and soft skills that are critical in order for pharma leaders and frontline employees to excel in ever-changing industry landscape, while explaining why these skills are beneficial when it comes to being proactive in handling talent shortages.
Expert insights. Personalized for you.
Let's personalize your content